Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02292225
Title IPI-145 With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Infinity Pharmaceuticals, Inc.
Age Groups: adult
Covered Countries USA | CAN

No variant requirements are available.